Drug intelligence / Profile preview

ramitine

Development stage: Preclinical
Lead developer: Huzhou Central Hospital
Administration: Oral

Overview

**Ramitine** is the English product name recorded in a prospective ChiCTR observational cohort study of bowel preparation before small-bowel capsule endoscopy. In that study, half a box of Ramitine is administered with one bottle of simethicone to assess intestinal cleanliness, patient tolerance, and safety. The publicly available trial record does not disclose Ramitine's active ingredient composition, manufacturer, dosage form, pharmacological target, or approved product labeling. ([chictr.org.cn](https://www.chictr.org.cn/showprojEN.html?proj=327696))

Brand names: Ramitine
Other names: 拉米汀

Beyond the preview

Go deeper on ramitine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ramitine.

Explore the full profile